MX376293B - Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva. - Google Patents

Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.

Info

Publication number
MX376293B
MX376293B MX2015011388A MX2015011388A MX376293B MX 376293 B MX376293 B MX 376293B MX 2015011388 A MX2015011388 A MX 2015011388A MX 2015011388 A MX2015011388 A MX 2015011388A MX 376293 B MX376293 B MX 376293B
Authority
MX
Mexico
Prior art keywords
mva
immune response
high dose
single high
protective immune
Prior art date
Application number
MX2015011388A
Other languages
English (en)
Other versions
MX2015011388A (es
Inventor
Ariane Volkmann
Cédric Cheminay
Mark Suter
Paul Chaplin
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of MX2015011388A publication Critical patent/MX2015011388A/es
Publication of MX376293B publication Critical patent/MX376293B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere al uso de un virus Ankara modificado (MVA) en la preparación de una vacuna para inducir una respuesta inmunitaria de protección contra un poxvirus en un sujeto recién nacido o lactante humano de menos de 6 meses de edad, en donde la vacuna tiene una dosis de al menos 108 de la dosis infectiva del 50% en cultivo de tejidos (TCID50) y en donde dicha vacuna induce respuestas de protección de linfocitos T y B contra un poxvirus en el recién nacido humano de menos de 6 meses de edad en ausencia de una segunda administración de MVA; y en donde el MVA es un virus MVA-BN depositado en la Colección Europea de Cultivos Celulares Animales (ECACC) bajo el No. De Acceso V00083008 o derivados de los mismos que no tienen capacidad de replicación reproductiva en la línea celular que queratinocitos humanos HaCat, la línea celular de riñón embrionario humano 293 (HEK293), la línea celular de osteosarcoma óseo humano 143B y la línea celular de adenocarcinoma de cuello uterino humano HeLa.
MX2015011388A 2013-03-15 2014-03-14 Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva. MX376293B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788722P 2013-03-15 2013-03-15
PCT/EP2014/000693 WO2014139687A1 (en) 2013-03-15 2014-03-14 Single high dose of mva induces a protective immune response in neonates and infants

Publications (2)

Publication Number Publication Date
MX2015011388A MX2015011388A (es) 2016-02-03
MX376293B true MX376293B (es) 2025-03-07

Family

ID=50389388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011388A MX376293B (es) 2013-03-15 2014-03-14 Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.

Country Status (17)

Country Link
US (1) US9707291B2 (es)
EP (2) EP2968524A1 (es)
JP (1) JP6480875B2 (es)
KR (1) KR102269491B1 (es)
CN (1) CN105101993A (es)
AU (4) AU2014231229A1 (es)
BR (1) BR112015021781A2 (es)
CA (1) CA2905569C (es)
EA (1) EA034825B1 (es)
HK (1) HK1216860A1 (es)
IL (1) IL241059B (es)
MX (1) MX376293B (es)
MY (1) MY175269A (es)
SG (2) SG10201707340XA (es)
UA (1) UA126785C2 (es)
WO (1) WO2014139687A1 (es)
ZA (1) ZA201507017B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968524A1 (en) * 2013-03-15 2016-01-20 Bavarian Nordic A/S Single high dose of mva induces a protective immune response in neonates and infants
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
MX2022015489A (es) * 2020-06-10 2023-03-22 Bavarian Nordic As Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117596D0 (en) * 1991-08-15 1991-10-02 John Gibson Lifting Gear Ltd Pulling system
US5471902A (en) * 1994-02-22 1995-12-05 Athenry Enterprises Limited Tuning system for pianos
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
DE20122302U1 (de) * 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
JP4801880B2 (ja) * 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ 新生仔予防接種用変異ワクシニアウイルスアンカラ
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
NO347468B1 (no) * 2005-02-23 2023-11-13 Bavarian Nordic As Et modifisert Vacciniavirus Ankara (MVA) for anvendelse ved immunisering.
WO2008028665A1 (en) * 2006-09-08 2008-03-13 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
US20120135032A1 (en) * 2009-10-08 2012-05-31 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
US9463238B2 (en) * 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
EP2864487B1 (en) * 2012-06-22 2018-12-05 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014019718A1 (en) * 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
EP2968524A1 (en) * 2013-03-15 2016-01-20 Bavarian Nordic A/S Single high dose of mva induces a protective immune response in neonates and infants

Also Published As

Publication number Publication date
BR112015021781A2 (pt) 2017-07-18
KR102269491B1 (ko) 2021-06-25
CN105101993A (zh) 2015-11-25
WO2014139687A1 (en) 2014-09-18
SG11201507192SA (en) 2015-10-29
AU2020260472A1 (en) 2020-11-26
EA201591803A1 (ru) 2016-02-29
CA2905569C (en) 2023-07-25
MY175269A (en) 2020-06-17
UA126785C2 (uk) 2023-02-08
AU2014231229A1 (en) 2015-09-17
US9707291B2 (en) 2017-07-18
ZA201507017B (en) 2018-12-19
IL241059B (en) 2020-10-29
KR20150129027A (ko) 2015-11-18
AU2019200977A1 (en) 2019-02-28
HK1216860A1 (zh) 2016-12-09
SG10201707340XA (en) 2017-10-30
IL241059A0 (en) 2015-11-30
CA2905569A1 (en) 2014-09-18
MX2015011388A (es) 2016-02-03
EP3708187A1 (en) 2020-09-16
EA034825B1 (ru) 2020-03-25
AU2022235527B2 (en) 2023-10-26
AU2022235527A1 (en) 2022-10-13
JP2016514114A (ja) 2016-05-19
EP2968524A1 (en) 2016-01-20
US20160030551A1 (en) 2016-02-04
JP6480875B2 (ja) 2019-03-13
NZ711569A (en) 2021-03-26

Similar Documents

Publication Publication Date Title
BR112017001796A2 (pt) composições de flagelina e seus usos
TN2015000185A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
BR112017014088A2 (pt) aparelho dentário que fornece superfícies oclusais expostas
JO3204B1 (ar) 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
PH12015501076A1 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
BR112019005329A2 (pt) composições de oligossacarídeos de leite humano purificadas
PH12016501974A1 (en) Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
MX2021013109A (es) Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.
PH12016501968A1 (en) Novel macrocyclic compounds
PH12017500637A1 (en) Inhibitors of lysine gingipain
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
MX376293B (es) Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.
MX368117B (es) Modulador de sabor y metodo para utilizar el mismo.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
MA40645A (fr) Préparation prébiotique à base d'inuline
PH12017500466A1 (en) Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of growth delay in infants or children
BR112013007308A2 (pt) vacina

Legal Events

Date Code Title Description
FG Grant or registration